BridgeBio Pharma, Inc. (BBIO)
NASDAQ: BBIO · Real-Time Price · USD
44.86
-0.26 (-0.58%)
At close: Jun 27, 2025, 4:00 PM
44.79
-0.07 (-0.16%)
After-hours: Jun 27, 2025, 6:55 PM EDT
BridgeBio Pharma Employees
As of December 31, 2024, BridgeBio Pharma had 730 total employees, including 725 full-time and 5 part-time employees. The number of employees increased by 174 or 31.29% compared to the previous year.
Employees
730
Change (1Y)
174
Growth (1Y)
31.29%
Revenue / Employee
$174,541
Profits / Employee
-$915,025
Market Cap
8.52B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 400,000 |
| Johnson & Johnson | 138,100 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 94,300 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 75,000 |
| AbbVie | 55,000 |
BBIO News
- 2 days ago - BridgeBio to Host Limb-girdle Muscular Dystrophy Type 2I/R9 Investor Webinar on Friday, July 11th at 8:00 am ET - GlobeNewsWire
- 24 days ago - BridgeBio: New Data Bolsters The Bull Case - Seeking Alpha
- 26 days ago - BridgeBio to Participate in the Goldman Sachs 46th Annual Global Healthcare Conference 2025 - GlobeNewsWire
- 5 weeks ago - Acoramidis Reduced Incidence of Atrial Fibrillation Events in Patients with ATTR-CM - GlobeNewsWire
- 5 weeks ago - Early and Sustained Increase in Serum TTR Levels by Acoramidis Independently Predicted Improved Survival in the ATTRibute-CM Study - GlobeNewsWire
- 6 weeks ago - BridgeBio Pharma Reports Inducement Grants under Nasdaq Listing Rule 5635(c)(4) - GlobeNewsWire
- 6 weeks ago - First Participant Dosed with Acoramidis in ACT-EARLY, the First Ever ATTR Primary Prevention Study - GlobeNewsWire
- 6 weeks ago - BridgeBio to Present Clinical Outcomes, Quality of Life Measures and Incidence of Atrial Fibrillation Events in Patients with ATTR-CM from the ATTRibute-CM Study at the Annual Congress of the Heart Failure Association of the ESC - GlobeNewsWire